Juikuang Rd, Neihu
Taipei 114, Taiwan
Part of the AbGenomics Group, including AbGenomics International Inc., a clinical-stage biopharmaceutical company located in the San Francisco Bay Area.
Involved in the discovery and development of therapeutic antibodies for immune-related inflammatory diseases, allergy, asthma, transplantation rejection, and cancer.
Lead candidate AbGn-168H (Neihulizumab) has demonstrated the proof of clinical efficacy in Phase II clinical trials for T-cell mediated diseases such as psoriasis and psoriatic arthritis.
Aims to discover, develop and bring to market novel small and large molecule drugs, with a focus on CNS and ophthalmology. Focus is on compound lead optimization to early clinical development.
(Bldg D, 6F, Biotechnology Building, Hsinchu Biomedical Science Park)
Creating new drug dosage forms using lipid-based microencapsulation for topical delivery and non-viral gene delivery systems.
Developing fully-human antibody-based biologics with novel mechanisms to fulfill unmet medical needs through proof-of-concept studies.
Has produced a portfolio of biologic leads with a primary clinical focus on cancer, autoimmune, and inflammatory diseases.
New drug development for cancer and eye diseases.
Covers the entire pharmaceutical supply chain from research and development to sales and distribution. Provides outsourced R&D and manufacturing services for domestic and multinational pharmaceutical companies. PIC/S certified.
Virtually operating company, focusing on developing new drugs in various areas including oncology and infectious disease. Focusing on translational medicine stage of drug development, team surveys many small molecules, peptides, biologics, and platform technologies at the lead optimization stage. Projects are brought into BRIM through co-development partnerships or in-licensing deals, and development of the projects is conducted at global CROs and CMOs that fit the needs of the project. Once clinical proof of concept (POC) is reached, the projects are partnered out for further clinical development.
Developer of immunotherapy for cancer treatment
Primarily generic pharmaceuticals. Strategy is to provide niche and high manufacturing complexity API and generic drugs, as well as 505(b)(2) class new drugs (new route of administration, new derivatives, new use, etc.).
Six manufacturing facilities in Taiwan.
Chunghwa Chemical Synthesis & Biotech Co., Ltd.: API manufacturer
Suzhou Chunghwa Chemical & Pharmaceutical Industrial Co., Ltd. (China)
Suzhou Chunghwa Yuming Pharmaceutical Co., Ltd. (China)
Chunghwa Yuming Healthcare Co., Ltd. (drug distribution)
Chunghwa Senior Care Co., Ltd. (seniors health care services)
Phermpep Co., Ltd. (peptide-based products for health)
Tai Rung Development Co., Ltd. (packaging products, ampoules, etc.)